Banco Santander SA ADR

Yahoo Finance • yesterday

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urti... Full story

Yahoo Finance • yesterday

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants âgés de deux à 11 a... Full story

Yahoo Finance • yesterday

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi Winthrop Industrie Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data f... Full story

Yahoo Finance • 4 days ago

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This report covers the seven major markets (7MM:... Full story

Yahoo Finance • 5 days ago

Artificial Intelligence in Pharmaceutical Market Research and Global Forecast Report 2026-2032

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Pharmaceutical Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The artificial intelligence in pharmaceutical mar... Full story

Yahoo Finance • 7 days ago

How The Sanofi (ENXTPA:SAN) Story Is Shifting As Fair Value And Assumptions Are Reworked

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Sanofi’s modelled fair value has been trimmed from €98.10 to €96.10, a shift that puts a roughly... Full story

Yahoo Finance • 7 days ago

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Sanofi Winthrop Industrie Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe... Full story

Yahoo Finance • 7 days ago

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale

Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale L’étude de phase 2b AIRCULES a atteint son... Full story

Yahoo Finance • 11 days ago

Mental Health Market Set to Surpass USD 668.62 Billion by 2035, Owing to the Increased Adoption of Digital Care and AI-Driven Therapies – SNS Insider

Austin, United States, April 03, 2026 (GLOBE NEWSWIRE) -- As per SNS Insider, The global Mental Health Market was estimated at USD 449.96 billion in 2025 and is projected to hit USD 668.62 billion by 2035, recording a CAGR of 4.04% over... Full story

Yahoo Finance • 12 days ago

Stocks to Watch Thursday: Apple, Exxon, ASML

↘️ Apple (AAPL), Nvidia (NVDA), Tesla (TSLA): The three tech stocks were the most heavily traded S&P 500 components before the U.S. bell. All fell, weighing on index futures. ↘️ UniCredit (IT:UCG), Deutsche Bank (XE:DB), Santander (ES:SAN)... Full story

Yahoo Finance • 13 days ago

Sector Update: Financial Stocks Rise Late Afternoon

Financial stocks advanced late Wednesday afternoon, with the NYSE Financial Index rising 0.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 13 days ago

Sector Update: Financial Stocks Higher in Afternoon Trading

Financial stocks advanced Wednesday afternoon, with the NYSE Financial Index rising 1.2% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 14 days ago

Seabridge Gold Provides Updated Mineral Resource Estimates for KSM Project

Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge") announced today updated Mineral Resource Estimates for its KSM Project located in northwestern British Columbia using metal price... Full story

Yahoo Finance • 14 days ago

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi Winthrop Industrie Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for pati... Full story

Yahoo Finance • 14 days ago

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte

Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans et plus atteints de GvHD chronique, off... Full story

Yahoo Finance • 17 days ago

Banco Santander AGM: Record €14.1B Profit, Bigger Dividend, New 2026-28 Plan Approved

Banco Santander logo Key Points Banco Santander reported record 2025 results with attributable profit of €14.1 billion (up 16% in constant euros), EPS +17%, RoTE of 16.3%, and announced total shareholder remuneration of about €7.05 billi... Full story

Yahoo Finance • 17 days ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressivel... Full story

Yahoo Finance • 17 days ago

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute

AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré 1x/4 sem. ou 1x/12... Full story

Yahoo Finance • 19 days ago

M&A Can Be a Big Opportunity. These Stocks Look Like They Could Pop If Deals Close.

One deal that should close in the next few months is Clearwater Analytics’ sale to a group of private money managers. Continue Reading... Full story

Yahoo Finance • 19 days ago

HSBC, Barclays, Nationwide and Halifax hike mortgage costs

Sub-4% mortgage deals have vanished from the UK market after most major lenders raised borrowing costs, as a fresh wave of rate increases sweeps through the sector following market jitters over the inflationary impact of the war in the Mid... Full story